Стратегия диагностики и лечения острого миелоидного лейкоза у детей
Диссертация
АКТУАЛЬНОСТЬ Острый миелоидный лейкоз (OMJI) является гетерогенной группой острых лейкозов, каждый из вариантов которой существенно отличается от других как по биологии опухолевой клетки, так и по прогнозу. В последние два десятилетия кроме морфоцитохимической характеристики лейкозных клеток появились сведения о поверхностных иммунологических антигенах и онтогенетических данных. Несмотря на то… Читать ещё >
Список литературы
- Аксель Е.М. Злокачественные новообразования у детей. //Съезд детских онкологов и гематологов России, И-ой, тез. докл. Ростов-на-Дону, 2001, с22.
- Байдун JI.B. Современная диагностика и классификация острой лейкемии. Острая миелоидная лейкемия. //Гематология и Трансфузиология.-1996.-Ы4.-с.35−39.
- Бене М.К., Кастолди Г., Напп В. И др. Предложения для иммунологической классификации острых лейкозов. //Гематология и Трансфузиология.-1996.-N6.-c.43−45.
- Волкова М.А. Влияние иммунологических и морфологических показателей на терапию больных острыми нелимфобластными лейкозами. //Материалы I всероссийского съезда гематологов 16−18 апреля-2002 г., Москва.
- Воробьёв А.И. //Руководство по гематологии. М.: Медицина, 1979, — с. 121.
- Воробьёв А.И. //Руководство по гематологии. -2002 М., Медицина с. 190
- Гальцева И.В., Паровичникова Е. Н., Савченко В. Г. Минимальная резидуальная популяция лейкемических клеток у пациентов с ОМЛ. //Терапевтический Архив.-1997.-т. 69-N.7-c.74−79.
- Домрачева Е.В., Асеева Е. А. Достижения и перспективы гематологической цитогенетики. //Гематология и Трансфузиология.-2001.-Ю.-с. 14−19.
- Кобзев Ю.Н. //Клиническая онкогематология,— М.: Медицина, 2001.- с.92−106.
- Масчан А.А., Алейникова О. В., Шнейдер М. М. Результаты пилотного протокола ОМЛ-2000 у детей. //Материалы I всероссийского съезда гематологов, 2002 г., Москва.
- Паровичникова Е.Н. //Материалы V российской онкологической конференции, 1999 г., Москва.
- Попа А.В. //Критерии прогноза и лечение острого нелимфобластного лейкоза у детей: Автореф. Дисс. к.м.н. 1996 — М.
- Попа А.В., Тупицин Н. Н., Маякова С. А. //Прогностическое значение иммунологических маркёров острого нелимфобластного лейкоза у детей. -Педиатрия.-1999-Ю-с.25−29.
- Пригожина Е.Л., Флейшман Е. В., Пучкова Г. П. //Клиническое значение хромосомных изменений при острых лейкозах. //Проблемы гематологии и переливания крови.-1982-т. 11-е. 10−16.
- Пригожина Е.Л., Флейшман Е. В., Пучкова Т. Н. (Prigogina E.L., Fleischman E.W., Puchkova G.N.) //Chromosomes in acute nonlymphocytic leukemia: Hum Genet.-1986-v.73-pp.l37−146.
- Пучкова Т.Н. //Хромосомные изменения при лейкозах у детей: Автореф. Дисс. к.м.н. — М., 1984.-c.21.
- Пяткин Е.К. //Руководство по гематологии. М.: Медицина — 1979- с. 131 137.
- Савченко В.Г., Паровичникова Е. Н., Исаев В.Г, и др. Острые промиелоцитарные лейкозы: эпоха новых знаний и достижений. //Гематология и Трансфузиология.-2001.-Ю.-с.26−35.
- Савченко В.Г., Паровичникова Е. Н., Исаев В. Г. и др. Результаты терапии острых миелоидных лейкозв взрослых. //Материалы IV российской онкологической конференции 1998 — Москва.
- Сергеев А.Г. Молекулярно-генетическая диагностика и прогноз лейкозов у детей// Автореф. дисс. д.м.н. -М. 1998.-c.29.
- Сергеев А.Г., Иванов Р. А., Фечина Л. Г. Опыт использования полимеразной цепной реакции для выявления хромосомных аберраций в детской онкогематологии.- //Гематология и Трансфузиология.-1999-К2-с.З-7.
- Тиганова О.А., Масчан А. А., Шнейдер М. М. и др. Результаты лечения острых миелоидных лейкозов у детей по протоколу НИИ детской гематологии ИДГ-ОМЛ-93. //Гематология и Трансфузиология.-2001-К4-с. 14−19.
- Тупицин Н.Н. Иммунофенотипическая характеристика гемобластозов человека и её клиническое значение: //Автореф. дисс. д.м.н. М.-1984-с.З-22.
- Тупицын Н.Н., Попа А. В., Маркина И. Г., Андреева Л. Ю., Волкова М. А., Маякова С. А., Френкель М. А., Петерсон И. С. Клиническое значение иммунофенотипа острых миелобластных лейкозов. //Гематология и трансфузиология 1999-T.44- № 3-с. 3−8
- Тупицин Н.Н. Клиническая онкогематология. //М.: Медицина 2001.-с. 131−135.
- Флейишан Е.В. Канцерогенез. //М.-Научный мир-2000-с.342−359.
- Френкель М.А. Клиническая онкогематология. //М.-Медицина-2001.-с.146−153.
- Херрингтон С, Макги Дж. Молекулярная клиническая диагностика. Методы. //М.: Мир.-1999-с.395.
- Aladjadi N., Auvringnon A., Leblanc Т. et al. Outcome for children with relapsed acute myeloid leukemia following initial treatment in the French ALME 89/91 protocol. //Med and Pediatr Oncol 2002 — v39 — N4 — p.236
- Appelbaum F, Molecular Diagnosis and Clinical Decisions in Adult Acute Leukemia. //Seminers in IIematology.-1999-v.36-N4-pp.401−410.
- Awisati G., Lo Coco F., Mandelli F. Acute Promyelocytic Leukemia: Clinical and Morphologic Features and Prognostic Factors. //Seminars in Hematology-2001-v.38-Nl-pp.4−12.
- Baehner RL. Kennedy A. Sather H. Characteristics of children with acute non-lymphocytic leukemia in long-term continuous remission: a report for Children’s Cancer Study Group. //Med Pediatr Oncol 1981 — 9 — p.393.
- Baer M.R., Steward C.C., Lawrence D. et al. Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and
- Survival in Acute Myeloid Leukaemia With t (8−21) (q22-q22). //Blood.-1997.-v.90- N4.-pp. 1643−1648.
- Bakhshi A, Jensen JP, Goldman P. et al. Cloning the chromosomal breakpoint of t (14:18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. //Cell 1985 — 41 p.899.
- Ball ED. Fanger MW. The expression of myeloid-specific antigens on myeloid leukemia cells: correlations with leukemia subclasses and implications for normal myeloid differentiation. //Blood 1983 — 61 — ph.456−464.
- Baranger L, Baruchel A. Leverger G. Schaison G. Berger R. Mono-somy-7 in childhood hemopoietic disorders. //Leukemia 1990 — 4 pp.345−352.
- Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the acute leukemias. //Br J Hemalol 1976 — 33 — pp.451−467
- Bennett JM. Catovsky D. Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia. //Ann Intern Med 1985 — 103 — pp.626 436.
- Berger R., Flandrin G., Bernbein A. et al. //Cancer Genet Cytogenet.-1987-v.29-pp.9−21.
- Betz SA. Foucar K. Head DR. Chen IM. Willman CL. False-posilive flow cytometnc platelet glycoprotein Ilh/IIla expression in myeloid leukemias secondary to platelet adherence to blasts. //Blood 1992 — 79 — pp.23 992 408.
- Billistrom R., Johansson В., Fioretos T. et al. Poor survival in t (8−21) (q22-q22)-associated acute myeloid leukaemia with leukocytosis. //Eur J Haematol.- 1997 -v.59 N1 — pp.47−52.
- Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. //Cancer-1997-v.80-Nll-pp.2191−2198.
- Bloomfield CD, Lawrence D, Byrd J. et al. Frequency of Prolonged Remission Duration after Hight-Dose Cytorabine Intensification in Acute Myeloid Leukaemia Varies by Cytogenetic Subtype. //Cancer Research.-1998-v.58-pp.4173−4179.
- Boultwood J. Lewis S. Wainscoat JS. The 5q-syndrome. //Blood 1994 — 84 -pp.3253−3261.
- Boultwood J. Fidler C. Chromosomal deletions in myelodysplasia. //Leuk Lymphoma 1995 — 17 — pp.71−79.
- Bradstock KF. Kirk J. Grimsley PG. Kahral A. Hughes WG. I’nusual immunophenotypes in acute leukaemias: incidence and clinical correlations. //Br J Haematol 1989 — 72 — pp.512−521.
- Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. //Proc Nati Acad Sci USA 1980 — 77 — pp.2936−2943.
- Brown P., Jurlander J., Pedersen-Bjergaard J. et al. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. //Leukemia Research.-1997.-v.21-N.10-pp.985−995.
- Brunning R.D., Matutes E., Harris N.L. et al. Summary of the WHO classification of tumours of haematopoietic and lymphoid tissues 2001.
- BuijsA. Shen-S, van Baal S. et al. Translation (12:22)(pI3:qll) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12pl3 to the MN1 gene on 22ql 1. //Oncogene 1995 -10 — pp.1511−1522.
- Buchanan GR. Hematologic supportive care. In: Pizzo PA. Poplack DC (eds). //Pediatric oncology. Philadelphia: JB Lippincott. 1993.
- Bunin NJ. Pui C-H. Differing complications of hyperleukocylosis in children with acute lymphoblaslic or acute nonlymphoblastic leukemia. //J Clin Oncol -1985−3-pp. 1590−1597.
- В usque L. Gilliland DG. Clonal evolution in acute myeloid leukemia, (editorial: comment) //Blood 1993 — 82 — pp.337−339.
- Butcher M, French R. Emperor J. et al. Molecular evidence that childhood monosomy 7 syndrome is distinct from juvenile chronic myel-ogenous leukemia and other childhood myeloproliferative disorders. //Genes Chromosomes Cancer -1995 12 — pp.50−58.
- Cassinat В., Zassadowski F., Balitrand N. et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t (15−17) translocation using real-time RT-PCR. //Leukemia.-2000-N14-pp.324−328.
- Chan LC. Pegram SM, Greaves MF. et al Contribution of immunopheno-type to the classification and differential diagnosis of acute leukemia. //Lancet 1985 — 1 -pp. 1475−1482.
- Cheson B, Cas. sileth P. Head D. et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. //J Clin Oncol 1990 — 8 — pp.813−914.
- Chessells JM. O’Callaghan U. Hardisty RM. Et al. Acute myeloid leukemia in childhood: clinical features and prognosis. //Br J Haematol 1986 — 6 — pp.555 564.
- Choi S-l. Simone JV. Acute nonlymphocytic leukemia in 171 children. //Med Pediatr Oncol 1976 — 2 — pi 19.
- Claxton D.F., Liu P., Hsu H.B. et al. Detection of Fusion Transcripts Generated by the Inversion 16 Chromosome in Acute Myeloid Leukemia. //Blood 1994 — v. 83-N7-pp. 1750−1756.
- Cleary ML, Smith SD, Sklar J. et al. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2 immunoglobulin transcript resulting from the t (14:18) translocation. //Cell 1986 — 47 — pp. 19−29.
- СI ft RA. Buckner CD. Thomas ED. Et al. The treatment of acute nonlym-phoblastic leukemia by allogeneic marrow transplantation. //Bone Marrow Transplant 1987 — 2 — pp.243−252.
- Cohen LF, BalowJE. Magrath IT. Et al. Acute tumor lysis syndrome: a review of 37 patients with Burkitt’s lymphoma. //Am J Med 1980 — 68 — pp.486−494.
- Costello R., Sainty D., Lecine P. et al. Detection of CBFp/MYHll fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. //Leukemia.-1997-N2-pp.644−650.
- Creutzig U. Ritter J. Riehm H. Improved results in childhood acute myelogenous leukemia: a report of the German cooperative study AML BFM 78. //Blood 1985 — 65 — pp.298−309.
- Creutzig U. Ritter J. Budde M. et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. //Cancer 1987 — 60 -pp.30−39.
- Creutzig U, Ritter J, Schellong G et al. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-AML-BFM-78. //Blood 1990 — 75 -pp.1932−1940.
- Creutzig U. Harbott J. Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. //Blood -1995 86 -pp.3097−3106.
- Creutzig U., Zimmermann M., Ritter J. etal. Definition of a standard-risk group in children with AML. //British Journal of Haematology 1999 — 104 — N3 -pp.630−639.
- Crist W. Boyett J, Pullen J. VanEys J, Vietti T. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. //Med Pediatr Oncol 1986 — 14 — pp. 135−143.
- Crist W, Boyett J, Jackson J. et al. Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. //Blood 1989 — 74 -pp. 1252−1260.
- Cross AH. Goorha RM. Nuss R. el al. Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical enlitv. //Blood 1988 — 72 — pp.579−586.
- Daniels JT., Davis BJ., Houde-McGrail L. et al. Clonal selection of CD56+ t (8−21) AML blasts: further suggestion of the adverse clinical significance of this biological marker? //British Journal of Haematology 1999 — 107 — 2 — pp.381 383.
- Dahl GV. Simone JV, Hustu HO. Et al. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. //Cancer 1978 — 42 -pp.2187−2195.
- Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the р210(Ьсг/аЫ) gene of the Philadelphia chromosome. //Science -1990 247 -pp.824−833.
- Diverio D., Pandolfi PP., Biondi A. et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. //Blood 1993 — 82 — 12 -pp.3556−3559.
- Diverio D., Riccioni R. t Pistilli A. et al. Improved rapid detection of the PML/RAR-alpha fusion gene in acute promyelocytic leukemia. //Leukemia 1996 — 10 — pp. 1214−1216.
- Donato NJ., Talpaz M. et al. Clinical Use of Tyrosine Kinase Inhibitors: Therapy for Chronic Myelogenous Leukemia and Other Cancers. //Clinical Cancer Research 2000 — 6 — pp.2965−2865.
- Drapkin RL. Gee TS. Dow lings MD. Prophylactic heparin therapy in acute promyelocytic leukemia. //Cancer 1978 — 41 — pp.2484−2492.
- Erickson P. Gao J. Chang KS. et al. Identification of breakpoints in t (8- 21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO. with similarity to Drosophila segmentation gene, runt. //Blood 1992 — 80 — pp. 18 251 833.
- Estey E.H., Shen Y., Thall P.F. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. //Blood 2000 — 95 -1 — pp.72−77.
- Feuron ER. Burke PJ, Schiffer CA. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. //N Engi J Med -1986 315 — pp.15−21.
- Exner M., Thalhammer R., Kapiotis S. et al. The «Typical» Immunophenotype of Acute Promyelocytic Leukemia (APL-M3): Does It Prove True for the M3-variant? //Cytometry 2000 — 42 — pp. 106−109.
- Faderl S., Kantarjian H. M., Talpaz M., Estrov Z. Clinical significance of minimal residual disease in leukemia (Review). //International Journal of Oncology 2000 — 17 — pp. 1277−1287.
- Fenaux P., Chevret S., Guerci A. et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. //Leukemia 2000 — 8 -pp. 1371−1377.
- Ferrara F., Di Noto R., Annunziata M. et al. Immunophenotypic analysis enables the correct prediction of t (8−21) in acute myeloid leukemia. //British Journal of Haematology 1998 — 102 — 2 — pp.444−448.
- Ferrara F., Morabito F., Martino B. et al. CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated
- With Simultaneous All-Trans-Retinoic Acid and Chemotherapy. //Journal of Clinical Oncology 2000 — 18 — 6 — pp.1295−1300.
- Fialkow PJ. Jacobson RJ. Papayannopoulou T. et al. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, ery-throcyte, platelet and monocyte/macrophage. //Am J Med 1977 — 63 — pp.125−131.
- Fialkow PJ. Singer JW. Adamson JW. et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. //Blood -1981 57 — pp.1068−1075.
- Fialkow PJ, Janssen J. Bartram C. et al. Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. //Blood 1991 — 77 — pp. 1415−1422.
- Filipits M., Stranzl Т., Pohl G. et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. //Leukemia 2000 — 1 — pp.68−76.
- Fourth International Workshop on Chromosome Translocations in Leukemia. //Genes Chromosomes Cancer 1984 — 11 — pp.249−258.
- FreedmanAS. Nadler LM. Cell surface markers in hematologic malignancies. //Semin Oncol 1987 — 14 — pp. 193−200.
- Fujisawa S., Togawa J., Tanaka M. et al. De novo acute myelogenous leukemia with trilineage myelodysplasia assosiated with t (8−21) (q22-q22). //Inrern Med 1999 — 38 — 7 — pp.607−611.
- Fujimaki S. t Funato Т., Harigae II. et al. A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cell with t (8−21) in periferial blood. //Eur J Haematol 2000 — 64 — pp.252−258.
- Gabert J. Detection of recurrent translocations using real time PCR- assessment of the technique for diagnosis and detection of minimal residual disease. //Haematologica 1999 — 84 — pp. 107−109.
- Grimwade D., Gorman P., Duprez E. et al. Characterization of Cryptic Rearrangements and Variant Translocations in Acute Promyelocytic Leukemia. //Blood 1997 — 90 — 12 — pp.4876−4885.
- Grimwade D., Walker H., Oliver F. et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trai. //Blood 1998 — 92 — 7 — pp.2322−2333.
- Grimwade D. The patogenesis of acute promyelocytic leukemia: evaluation of the role of molrcular diagnosis and monitoring in the management of the disease. //British Journal of Haematology 1999 — 106 — pp.591−613.
- Golub TR, Barker GF. Lovett M. et al Gilliland DG. Fusion of PDGF receptor to a novel ets-like gene TEL in chronic myelomonocytic leukemia with t (5:12) chromosomal translocation. //Cell 1994 — 77 — pp.307−313.
- Golub TR, Barker GF. Bohlander SK. et al. Fusion of the TEL gene on 12pl3 to the AMU gene on 21q22 in acute lymphoblastic leukemia. //Proc Nati Acad Sci U S A 1995 — 92 — pp.4917−4924.
- Gorin NC. Aegerter P. Aubert B. et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. //Blood 1990 — 75 — pp.1606−1614.
- Gralnick HR., Bagley J., Abrell E. et al. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. //Am J Med 1972 — 52 -pp.167−173.
- Grund FM., Armitage JO., Bums CP. et al. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. //Arch Intern Med 1977 — 37 -pp. 1246−1252.
- Grier HE., Gelber RD., Camitta BM. et al. Prognostic factors in childhood acute myelogenous leukemia. //J Clin Oncol -1987 5 — pp. 1026−1032.
- Griffin JD. RitzJ, NadlerLM. et al. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. //J Clin Invest 1981 — 68 — pp.932 940.
- Griffin JD. Davis R. Nelson DA. et al. L’se of surface marker analysis to predict outcome of adult acute myelohlastic leukemia. //Blood 1986 — 68 — pp. 12 321 240.
- Griffin JD. Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986- 68:1185.
- Groopman J. Ellman L. Acute promyelocytic leukemia. //Am J Hematol -1979 7 — pp.395−401.
- Haferlach Т., Bennett J. M., Lofjler H. et al. Acute Myeloid Leukemia with Translocation (8−21). Cytomorfology, Dysplasia and Prognostic Factors in 41 Cases. //Leukemia and Lymphoma 1996 — 23 — pp.227−234.
- Hathorn JW. Pizzo PA. Infectious complications in the pediatric cancer patient. In: Pizzo PA, Poplack DC (eds). //Pediatric oncology. Philadelphia: JB Lippincott -1988 8 — pp.37−40.
- Hayashi Y., Sugita K., Nakazawa S., et al. karyotypic patterens in acute mixed lineage leukemia. //Leukemia 1990 — 4 — pp.121−127
- Helm S., Mitelman F. Cancer Cytogenetics second edition. New York, Chichester, Brisbane, Toronto, Singapore. //Wiley-Liss -1995
- Huang ME, Ye YC. L’se of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. //Blood 1988 — 72 — pp.567−577.
- Hurwitz CA. Mounce KG, Grier HE. et al. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. //J Pediatr Hematol Oncol 1995 — 17 — pp.185−191.
- Jacobson RJ. Temple MJ, Singer JW. et al. A clonal complete remission in a patient with acute nonlymphocytic leukemia originating in a multipo-tent stem cell. //N Engl J’Med -1984 310 — pp.1513−1519.
- Jansen HJ., de Ridder M.C., Geertsma W.M.C. et al. Complete Remission of t (ll-17) Positive Acute Promyelocytic Leukemia Induced by All-trans Retinoic Acid and Granulocyte Colony-Stimulating Factor. //Blood 1999 — 94 — 1 — pp.3945.
- Jurcic J.G., Nimer S.D., Scheinberg DA. et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. //Blood 2001 — 98 — 9 — pp.26 512 656.
- Kalwinsky D, Raimondi S. Scnell M. Prognostic importance ofcyto-genetic subgroups in de novo pediatric acute nonlvmphocytic leukemia. //J Clin Oncol -1990 8 — pp.75−82.
- Kanda Y., НатаН Т., Yamamoto R. et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia. //Cancer 2000 — 88 -11 — pp.2529−2533.
- Katano N., Tsurusawa M., Hirota T. et al. Cytogenetic abnormality and prognosis in childhood acute myeloblastic leukemia. Children’s Cancer and Leukemia Study Group (CCLSG). //Rinsho Ketsueki 1997 — 38 — 8 — p.647 (abstract).
- Kondo M., Kudo K., Kimura H. et al. Real-time quatitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t (8−21)-positive acute myelgenous leukemia. //Leukemia Research -2000 24 — pp.951−956.
- Krauter J., Wattjes MP, Nagel S. et al. Real-time RT-PCR for the detection and qualification of AML1/MTG8 fusion transcripts in t (8−21)-positive AML patients. //British Journal of Haematology 1999 — 107 — pp.80−85.
- Krischer JP. Steuber CP. Vietti TJ. et al. Long-term results in the treatment of acute nonlymphocytic leukemia: a Pediatric Oncology Group study. //Med Pediatr Oncol-1989- 17 pp.1401−1408.
- Kusec R., Laczika K., Knbol P. et al. AML1-ETO fusion mRNA can be detected in remission blood samples of all patients with t (8−21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. //Leukemia 1994 — 8 — pp.735−739
- Kwong Y.L., Path M.R.C., Chan V. et al. Use of the Polymerase Chain Reaction in the Detection of AML1/ETO Fusion Transcript in t (8−21). //Cancer -1995 75 — pp.821−825.
- Lampkin ВС, Masterson M. Sambrano JE. et al Current chemotherapeutic treatment strategies in childhood acute nonlymphocytic leukemia. //Semm Oncol -1987 14 — pp.397−402.
- Lampkin ВС. Lange B. Bernstein /. et al. Biologic characteristics and treatment of acute nonlymphocytic leukemia in children: report of the ANLL Strategy
- Group of the Childrens Cancer Study Group. //Pediatr Clin North Am 1988 -35 -pp.743−750.
- Lanhan G. Dahl G. Billings F. Stass S. et al. Pseudomonas aeruginase infection with marrow suppression simulating acute promyelocytic leukemia. //Am J Clin Pathol 1983 — 80 — pp.404−500.
- Larson RA., Kondo K., Vardiman J. W., Butler A.R., Golomb H.M., Rowley J.D. Evidence for a 15- 17 translocation in every patient with acute promyelocytic leukemia. //American Journal of Medicine 1984 — 76 — pp.827−835.
- Lea JW, Masys DR. Shackford SR. et al. Typhiliiis: a treatable complication of acute leukemia therapy. //Cancer Clin Trials 1980 — 3 — pp.355−361.
- Le Beau M.M., Larson R.A., Bitter MA. et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. //New England Journal of Medicine 1983 — 309 — pp.630−636.
- Lekanne DR. Riegman PH. Groen NA. et al. Cloning and characterization of MN1. a gene from chromosome 22qll, which is disrupted by a balanced translocation in a meningioma. //Oncogene 1995 — 10 — pp. 1521−1528.
- Lichtman MA. RoweJM. Ilyperleukocytic leukemias: rheological. .iinical and therapeutic considerations. //Blood 1982 — 60 — pp.279−284.
- Liso V., Albano F., Pastore D. et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. //Haematologica 2000 — 85 — 12 — pp. 1285−1290.
- Liu P., Tarle S. A., Hajra A. et al. Fusion Between Transcription Factor CBFp/PEBPp and a Myosin Heavy Chain in Acute Myeloid Leukemia. //Science -1993 261 — pp.1041−1044.
- Lo CF. Pelicci PG, D’Adamo F, et al. Polyclonal hematopoietic recon-stitution in leukemia patients at remission after suppression of specific gene rearrangements see comments. //Blood 1993 — 82 — pp.606−613.
- Lo Coco F., Diverio D., Pandolfi PP et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. //Lancet 1992 -340 — p.1437 (abstract).
- Lo Coco, Nervi C., Avvisati G., Mandelli F. Acute promyelocytic leukemia: a curable disease. //Leukemia 1998 — 12 — pp. 1866−1880.
- Lo Coco F., Diverio D., Awisati G. et al. Therapy of Molecular Relapse in Acute Promyelocytic Leukemia. //Blood 1999 — 94 — 7 — pp.2225−2229.
- Ludwig W-D. Bartram CR. Ritter J. el al. Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by mul-tiparameter analysis. //Blood 1988 71 — pp. 1518−1527.
- Marco F, Bureo E, Ortega JJ et al. // High survival rate in infant acute leukemia treated with early high-dose chemotherapy and steam-cell support. Groupo Espanol de Transplante de Meula Osea en Ninos. //J Clin Oncol 2000 — 18 -18-pp. 3256−3261
- Marcucci G., Caligiuri MA, Dohner H. et al. Quntification of CBFp/MYHll fusion transcript by Real Time RT-PCR in patients with INV (16) acute myeloid leukemia. //Leukemia 2001 — 15 — pp.1072−1080.
- Martin G., Barragan E., Bolufer P. et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFp/MYHll rearrangement. //Haematologica 2000 — 85 -pp.699−703.
- Martinez-Climent JA, Lane NJ., Rubin C.M. et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. //Leukemia 1995 — 1 — pp.95−101.
- Martinez-Climent JA, Garcia-Conde J. Chromosomal Rearrangements in Childhood Acute Myeloid Leukemia and Myelodysplastic Syndroms.//Journal of Pediatric Hematology. //Oncology 1999 — 21 — 2 — pp.91−102.
- Maruyama F., Stass SA., Estey E. et al. Detection of AML1-ETO fusion transcript as a tool for diagnosis t (8−21) positive acute myelgenous leukemia. //Leukemia 1994 — 8 — pp.40−45.
- Mayer RJ. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. //Semin Oncol -1987 -14 pp.384−392.
- McWTiirter JR, Wang JYJ. An actin-binding function contributes to transformation by the Bcr-AbI oncoprotein of Philadelphia chromsome positive human leukemias. //EMBO J 1993 — 12 — pp. 1533−1539.
- Meshinchi S., Woods W. G., Stirewalt D. et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. //Blood 2001 — 97 — pp.89−94.
- Meyers S, Lenny N. Iliebert 5W. et al. The t (8:21) fusion protein interferes with AML-1B—dependent transcriptional activation. //Mol Cell Biol 1994 — 15 -pp.1974−1981.
- MehtaJ., Powles R., TreleavenJ. et al. The Imact of Karyotype on Remission Rates in Adult Patients with de novo Acute Myeloid Leukemia Receiving High
- Dose Cytarabine-Based Induction Chemotherapy. //Leukemia and Lymphoma -1999 34 — pp.553−560.
- Miller WH, Levine K., DeBlasio A. et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. //Blood 1993 — 82 — 6 -pp.1689−1694.
- Mitelman F., Heim Sverre. Quantitative Acute Leukemia Cytogenetics. //Genes, Chromosomes & Cancer 1992 — 5 — pp.57−66.
- Mitelman F., Johansson В., Mertens F. Catalog of Chromosome Aberrations in Cancer. //N.Y.: Wiley. Liss 1994.
- Mirro J. ZipJTF, Pui C-H. el al. Acute mixed lineage leukemia: clinico-pathologic correlations and prognostic significance. //Blood 1985 — 65 — pp. 11 151 120.
- Miyamoto Т., Weissman /., Akashi K. et al. AMLl/ETO-expressing nonleukemiac stem cells in acute myelogenous leukemia with 8−21 chromosomal translation. //Proc. Natl. Acad. Sci 2000 — 97 — 13 — pp.7521−7526.
- Mrozek K., Heinonen K., Bloomfield C. et al. Clinical importance of cytogenetics in acute myeloid leukemia. //Best Pract Res Clin Haemat 2001 — 1 -pp. 19−47.
- Mrozek К., Heinonen К., de la Chapelle A., Bloomfield C. Clinical Significance of Cytogenetics in Acute Myeloid Leukemia. //Seminsrs in Oncology 1997 — 24 — pp. 17−31.
- Murray C.K., Estey E., Paietta E. et al. CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome? //J Clin Oncol -1999 17 -1 — p.293 (abstract).
- Nakano Y., Naoe Т., Kiyoi H. et al. Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. //Leukemia Research 2000 — 24 — 4 -pp.349−352.
- Naoe Т., Kiyoe H., Yamamoto Y. et al. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. //Cancer Chemother Pharmacol 2001 -48- l-p.27(abstract).
- Nucifora G., Larson R., Rowley J.D. Persistence of the 8−21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. //Blood -1993 82 — pp.712−715.
- Nucifora G., Bbegy C., Kobayashi IL, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genesat3q26 in (3−21)(q26-q22) translocations. //Proc Natl Acad Sci USA 1994 — 91 -pp.4004−4010.
- Nucifora G., Rowley J.D. Ami 1 and the 8−21 and 3−21 traslocations in acute and chronic myeloid leukemia. //Blood 1995 — 86 — pp. 1−9.
- Odom LF. Gordon EM. Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. //Blood 1984 — 64 -pp.875−882.
- Okuda TDJ. Hiebert SW, Grosveld G. Downing JR. AML1 the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. //Cell 1996 — 84 — pp.321−328.
- O’Reaan, Carson S, Chesney RW. Electrolyte and acid-base disturbances in the management of leukemia. //Blood 1977 — 49 — pp.345 350.
- Pagliaro LC, Stanley WS. Interphase FISH and morphologic analysis ofAML. //Cancer Genet Cytogenet 1993 — 67 — pp.95−101.
- Papadopoulos P. Ridge SA, Boucher CA, Stocking C. Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. //Cancer Res 1995 — 55 — pp.34−43.
- Pedersen-Bjergaard J. Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different waysand may contribute differently to malignant transformation. //Blood 1994 — 83 -pp.2780−2787.
- Pizzo PA. Infectious complications in the child with cancer: I. Pathophysiology- II. Management- III. Prevention. //Pediatrics 1981 — 98 — pp.341−348.
- Preisler H, Danis RB. Kirshner J. et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group В study. //Blood 1987 -69-pp. 1441−1448.
- Pui C-H. Dahl GV. Kalwinslcy DK. et al. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. //Blood 1985 — 66 — pp. 10 621 070.
- Pui C-H. Kalwinskv D. Schell MJ. Acute nonlymphohlastic leukemia in infants. //J Clin Oncol 1988 — 6 — pp.1008−1018.
- Pui C-H, Behm F.G., Sight B, et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. //Blood 1990 — 75 — pp. 198−207.
- Pui C-H. Raimondi SC. Head DR. el al. Characten/ation of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. //Blood 1991 — 78 — pp. 1327−1336.
- Pui C.H., Raimondi S.C., Srivastava D.K. et al. Prognostic factors in infants with acute myeloid leukemia. //Leukemia 2000 — 4 — pp.684−687.
- Radich J.P. Clinical applicability of the evaluation of minimal residual disease in acute leukemia. //Curr Opin Oncol 2000 — 12 — pp.36−40.
- Rai KR. Hollad JF, Glidewill OJ. Treatment of acute myelocytic leukemia: a study of Cancer and Leukemia Group B. //Blood 1981 — 58 — pp.1203−1210.
- Raimondi SC. Kalwinsky DK. Hayashi Y Behm FG. Mirro J J. Williams DL. Cytogenetics of childhood acute nonlymphocytic leukemia. //Cancer Genet Cytogenel 1989 — 40 — pp. 13−21.
- Ravindranath Y, Steuber CP, Krischer J. et al. High dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. //J Clin Oncol 1991 — 9 — pp.572−579.
- Ravindranath Y. Abella E, Krischer JP. et al. Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. //Blood 1992 — 80 — pp.2210−2218.
- Raynaud S. Cave H. Baens M. et al. The 12:21 translocation involving TEL. and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. //Blood 1996 — 87 — pp.2891−2899.
- Ritterbach J. Harbott J. Ritter J, Lampert F. Chromosomal aberrations in childhood acute nonlymphoblastic leukemia. //Hamatologi und Blut-transfusion -1990 -p.153.
- Romana SP, Poirel H. Leconiat M. et al. High frequency of the t (12:21) in childhood B-lineage acute lymphoblastic leukemia. //Blood 1995 — 86 — pp.42 634 270.
- Rombouts WJC, Blokland /., Lowenberg B. et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplication in the Flt3 gene. //Leukemia 2000 — 14 — pp.675−683.
- Ross DD. Novel mechanisms of drug resistance in leukemia.//Leukemia -2000 3 — pp.467−473.
- Rowley J.D., Golomb H.M., Dougherty et al. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. //Lancet 1972 — 1 -pp.549−550.
- Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. //Ann Genet 1973 — 16 — pp. 109−112.
- Rowley J.D. Cytogenetic Analysis in Leukemia and Lymphoma: an Introduction. //Seminars in Hematology 2000 — 37- 4 — pp.315−319.
- Rowley J.D. Molecular genetics in acute leukemia. //Leukemia 2000 — 3 -pp.513−517.
- Rowley J.D. The Role of Chromosome Translocations in Leukemogenesis. //Seminars in Hematology 1999 — 36 — 4 — pp.59−72.
- Rubin C. Arthur D. Woods W. et al. Therapy related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. //Blood 1991 — 78 — pp.2982−2989.
- Rubnitz JE, Behm FG, Downing JR. et al. Uq23 rearrangements in acute leukemia. //Leukemia 1996 — 10 — 74.
- Rubnitz J.E., Raimondi S.C., Tong H. Favorable Impact of the t (9-ll) in Childhood Acute Myeloid Leukemia. //J Clin Oncol 2002 — 20 — 9 — pp.23 022 309.
- Sakata N., Окатига Т., Inoue M. et al Rapid Disappearance of AML1-ETO Transcripts in Patients with t (8−21) Acute Myeloid Leukemia Following Bone Marrow Transplantation and Chemotherapy. //Leukemia and Lymphoma — 1997 -26-pp. 141−152.
- Sallan SE, Ritz J, Pesando J. et al. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. //Blood — 1980 55 -pp.395−362.
- Shamberger RC. Weinstein HJ. Delorey MJ. et a. I The medical and surgical management of typhlitis in children with acute myelogenous leukemia. //Cancer -1986 57 — pp.603−601.
- Sanders JE. Thomas ED, Buckner CD. Marrow transplantation of children in first remission of acute nonlymphboastic leukemia: an update. //Blood 1985 — 66 — pp.460−469.
- Schiffer CA, Lee EJ. Tomiyasu T. et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. //Blood -1989 73 — pp.263−270.
- Schnittger S., Kinkelin U., Schoch C. et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. //Leukemia 2000 — 5 — pp.796−804.
- Schnittger S., Weisser M., Schoch С et al Quantitative PCR in Acute Myeloid Leukemia at Diagnosis and during Follow Up: Impact on Predicting Outcome. //Blood 2001 — 98 — 11 — Abstract # 1916.
- Schoch C., Haase D. t Haferlach T. et al. Fifty-one patients with acute myeloid leukemia and translocation t (8−21) (q22-q22): an additional deletion in 9q is an adverse prognostic factor. //Leukemia 1996 — 10.-pp. 1288−1295.
- Seung T.L., Joon IIJ., Yoo II.M. et al. AC133 antigen as a prognostic factor in acute leukemia. //Leukemia Research 2001 — 25 — 9 — pp.757−767.
- Shome DK. Gupta NK. Prajapati NC, Raju GM. Choudhury P. Dubey AP. Orbital granulocytic sarcomas (myeloid sarcomas) in acute nonlymphocytic leukemia. //Cancer 1992 — 70 — pp.2298−2304.
- Shurtleff SA. Buijs A. Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t (12:2I) is the most common genetic lesion in pediatric ALL and defines a subgoup of patients with an excellent prognosis. //Leukemia 1995 — 9 — pp. 19 852 892.
- Slavin RE, Dias MA. Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients. //Cancer 1978 — 42 — pp. 1747−1753.
- Soekarman DLM, Daenen SJB, Fonatsch C. et al. The translocation t (6- 9) (p23: q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. //Blood 1992 — 79 — pp.2990−2997.
- Steuber CP, Civin C. Krischer J. et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. //J Clin Oncol 1991 — 9 — pp.247−254.
- Stirewalt D.L., Willman C.L., Radich J.P. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplication are highly sensitive and specific. // Leukemia Research 2001 — 25 — pp.1085−1088.
- Stone RM. Maguire M, Goldberg MA. et al. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. //Blood 1988 -71 — pp.690−698.
- Sugimoto Т., Das H., Imoto S. et al. Quantitation of Minimal Residual Disease in t (8−21)-Positive Acute Myelgenous Leukemia Patients Using Real-Time Quantitative RT-PCR. //Am J Hematol 2000 — 64 — pp. 101−106.
- Swirsky D. Li S, Matthews J. Flemans R, ReesJ. Hayhoe F. 8:21 Translocation in acute granulocytic leukemia: cytological. cytochem-ical. and clinical features. //Br J Haematol 1984 — 56 — pp. 199−205.
- Taguchi J., Miyazaki Y., Yoshida S. et al. Allogenic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD). //Leukemia 2000 — 11 — pp.1861−1866.
- Tallman MS. Therapy of acute myeloid leukemia. //Cancer Control 2001 — 8 -1 — pp.62−78.
- Thirman MJ, Gill HJ. Burnett RC. et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with llq23 chromosomal translocations. //N Engl J Med 1993 — 329 — pp.909−915.
- Tiedemann K., Waters K.D., Tauro G.P., et al. //Results is intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first remission. //Blood 1993 — 82 — 12 — pp.3730−3778.
- Tien II-F. Wang C-H. Su I. et al. A subset of acute nonlymphocytic leukemia with expression of surface antigen CD7: morphologic, cy to-chemical, immunocytochemical and T cell receptor gene analysis on 13 patients. //Leuk Res -1990−14-pp.515−521.
- Tighe JE. Daga A. Calabi F. Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in U8:21) of acute myeloid leukemia. //Blood -1993 81 — pp.592−599.
- Tobal K., Liu Yin J. Monitoring of Minimal Residual Disease by Quantitative Reverse Transcriptase-Polymerase Chain Reaction for AML1-MTG8 Transcripts in АМЬМ2 With t (8−21). //Blood 1996 — 88 — 10 — pp.3704−3709.
- Tobal K., Newton J., Macheta M. et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t (8−21) can identify patients indurable remission and predict clinical relapse. //Blood 2000 — 95 — 8 — pp.815 819.
- Tobal K., Moore H., Macheta M., Liu Yin JA. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARa transcripts with a sensitive competitive RT-PCR method. //Leukemia 2001 — 15 — pp. 1060−1065.
- Tse KF., Novelli E., Civin CI. et al. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. //Leukemia 2001 — 7 -pp. 1001−1010.
- Vellenga E. Young DC. Wagner K. Wiper D. Ostapovicz D, Griffin JD. The effects ofGM-CSF and G-CSF in promoting growth ofclonogenic cells in acute myeloblasts leukemia. //Blood 1987 — 69 — pp.771−777.
- Venditti A, Buccisano F, Del Poeta G et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. //Blood -2000 96 — 12 — pp.3948−3952.
- Virtaneva K., Wright F., Tannet S. et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. //PNAS 2001 — 98 — 3 — pp. 1124−1129.
- Worrell RP. de The H, Wang Z-Y. Degos L. Acute promyelocytic leukemia. //N Engi J Med 1993 — 329 — pp.177−184.
- Wattjes MP, Krauter J., Nagel S. et aL Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1-MTG8 fusion transcripts in t (8−21) positive acute myelgenous leukemia. //Leukemia 2000 -14 — pp.329−335.
- Webb D.K.H., Harrison G., Stevens R.F. et al. Relationship between age at diagnosis, clinical features and outcome of therapy in children treated in the
- Medical Research Council AML 10 and 12 trails for acute myeloid leukemia. //Blood 2001 — 98 — 6 — pp. 1714−1720.
- Weiner M. Borowitz M. Boyett J, et al. 1'tPO: Clinical pathologic aspects of myeloid antigen positively in pediatric patients with acute lym phoblastic leukemia (ALL). //Proc Am Soc Clin Oncol 1985 — 4 — p. 172. (abstract).
- Weinstein HJ, Mayer RJ. Rosenthal DS. Treatment of acute myelogenous leukemia in children and adults. //N Engl J Med 1980 — 303 — pp.473−380.
- Weinstein HJ, Mayer RJ, Rosenthal DS. et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. //Blood 1983 — 62 -pp.315 321.
- Weiner M. Borowitz M. Boyett J, et al. 1'tPO: Clinical pathologic aspects of myeloid antigen positively in pediatric patients with acute lym phoblastic leukemia (ALL). //Proc Am Soc Clin Oncol 1985 — 4 — p. 172. (abstract).
- Wiemik P. SerpickAA. Granulocytic sarcoma (chloroma). //Blood 1970 — 35 — pp.361−368.
- Wiernik P., Kim II., Gundacker H. et al. Prognostic Implication of Additional Cytogenetic Aberrations in De Novo Acute Myeloid Leukemia (AML) with t (15−17), t (8−21) or inv (16)/t (16−16). // Blood 2001 — 98 — 11 — Abstract # 1913.
- Wiersma S.R., Ortega j., Sobel E., Weinberg K.L. Clinical importance of myeloidantigen expression in acute lymphoblastic leukemia of childhood. //N Engl L Med 1991 — 344 — pp.800−806.
- Willman C.L. Molecular Evaluation of Acute Myeloid Leukemias. //Seminars in Hematology 1999 — 36 — 4 — pp.390−400.1. Q &
- Woods WG. Nesbit ME, Buckley J, et al. Correlation of chromosome abnormalities with patient characteristics, histologic subtype, and induction success in children with acute nonlymphocytic leukemia. //J Clin Oncol 1985 — 3 — pp.310.i
- Woods WG., Ruyman FB, Lampkin B. et al. The role of timing of high-dose •tcvtosme arabinoside intensification and of maintenance therapy in the treatment of, children with acute nonlymphocytic leukemia. //Cancer 1990 — 66 — pp. 11 061 112.
- Woods WG, Kobrinsky N. Buckley J. et al. Timing intensive induction therapy improves postremission outcome in acute myeloid leukemia (AML) irrespective of the use of bone marrow transplantation (BMT). //Blood 1994 — 84 — Abstract # 232a.
- Yamamoto Y., Kiyoi H., Nakano Y. et al Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. //Blood 2001 -97 — 8 — pp.2434−2439.
- Zutter MM. Martin PJ. Hanke D. Kidd PG. et al. CD7+ acute non-lympho-cytic leukemia: evidence for an early multipotnetial progenitor. //Leuk Res 1990 -14 — pp.23−30.
- Zittoun RA, Mandelli F, Willemze R, et al. Autologus or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. //N Engl J Med 1995 — 332 — pp.217−223.